Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Fentanyl vs IV PCA for Breakthrough Cancer Pain
NCT05053308Withdrawn
- Sponsor
- Seoul National University
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP) (2 arms), sponsored by Seoul National University. Primary endpoint: Change in 11-point scale NRS pain score at 30 minutes. Planned start Dec 2022; status: withdrawn.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT05053308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053308.